Measles, mumps, and rubella virus vaccine (M-M-R™II): a review of 32 years of clinical and postmarketing experience.
about
Vaccination of healthcare workers: A reviewPolyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytesThe Capricious Nature of Bacterial Pathogens: Phasevarions and Vaccine DevelopmentAcute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systemsA signal detection method for temporal variation of adverse effect with vaccine adverse event reporting system dataSingle nucleotide polymorphisms/haplotypes associated with multiple rubella-specific immune response outcomes post-MMR immunization in healthy children.Sendai virus as a backbone for vaccines against RSV and other human paramyxovirusesA novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity.Trends in childhood measles vaccination highlight socioeconomic inequalities in Vietnam.Vaccine-induced measles virus-specific T cells do not prevent infection or disease but facilitate subsequent clearance of viral RNA.Encephalitis followed by optic neuritis: a case report and review of literature.Antitumor Virotherapy by Attenuated Measles Virus (MV).Current progress in pulmonary delivery of measles vaccine.Vaccine technologies: From whole organisms to rationally designed protein assemblies.PACT- and RIG-I-Dependent Activation of Type I Interferon Production by a Defective Interfering RNA Derived from Measles Virus Vaccine.Mumps clinical diagnostic uncertainty.Measles Vaccination is Best for Children: The Argument for Relying on Herd Immunity Fails.A Case of Post Encephalitic Optic Neuritis: Clinical Spectrum, Differential Diagnosis and Management.Measles-containing vaccination rates in southern Alberta.
P2860
Q26796300-BC7EE210-417E-4606-AF67-9BF95D4E56DFQ26852816-70577E86-C8B8-49EE-BE56-50903D335E7DQ28074750-FAE9DCBE-9866-4652-AA28-0A20D20D00A5Q28534419-5222A4E7-9672-49E5-880F-23B46F7A2129Q33896441-B72DB287-F929-4E61-81EA-5C55AF80F552Q36104082-55B68C00-199F-4CCE-971C-4507529F5ACFQ37118707-6C0CCAC1-E93B-4C8B-B29D-34E40C4089C6Q37388411-4DF66DF1-E9CC-45E5-B6D2-071F5DAF4BE9Q37697458-D08E94D3-FD23-4040-B433-ECA3A40C6A05Q37714080-423DEF7E-1E7A-4152-9442-10DEA698840AQ38172508-EA01CF2D-EF31-4F2D-BEA6-9E790C5D24F4Q38212137-67FC25B5-BD87-4185-85EE-73F1CE47D2F6Q38212517-A433F8AE-9B4A-43AC-9A7E-CDB7EBE0140BQ38806558-38BF06DF-8144-409D-855C-AFEF780E64FDQ38816586-8264DBAB-F6B5-48A3-909A-A032045D9000Q40152653-7F4917CB-34D2-41F9-B74B-DE23FB2F7574Q53722084-EE20D917-662A-4E45-9C08-42A0BDF6E6BBQ54222900-6B1C7328-72C8-4879-BA3D-D4194F6533ECQ55009161-9C18F748-5120-42E6-A484-489A48B0A089
P2860
Measles, mumps, and rubella virus vaccine (M-M-R™II): a review of 32 years of clinical and postmarketing experience.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Measles, mumps, and rubella vi ...... and postmarketing experience.
@en
type
label
Measles, mumps, and rubella vi ...... and postmarketing experience.
@en
prefLabel
Measles, mumps, and rubella vi ...... and postmarketing experience.
@en
P2093
P1433
P1476
Measles, mumps, and rubella vi ...... and postmarketing experience.
@en
P2093
Adrian Dana
Fabio Lievano
Kristen A Vagie
Manisha A Amin
Margaret M Seminack
Michele Thornton
Richard T Wiedmann
Susan A Galea
Susan B Manoff
Trung N Tran
P304
P356
10.1016/J.VACCINE.2012.08.057
P407
P577
2012-09-07T00:00:00Z